First, the triple modulator 41, which exhibits only approximately 1/5 of the FXR activation efficacy of OCA, did not markedly reverse steatosis as first hallmark of NAFLD suggesting that strong FXR activation efficacy is required to reduce hepatic fat content. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.